Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935859 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL29474981 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL29041073 | 0.84 | HTR2C (0.51) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL27845790 | 0.83 | TSHR (0.44) | HTR2CHTR2AHTR2BCYP19A1DRD2 | |
| SCHEMBL7786361 | 0.82 | CYP19A1 (0.49) | CYP19A1ADRA1ATSHR | |
| SCHEMBL4753995 | 0.80 | ALDH1A1 (0.41) | HTR2CHTR2AHTR2BDRD2ADRA1A | |
| SCHEMBL30949067 | 0.80 | HTR2C (0.47) | HTR2CHTR2AHTR2BDRD2MEN1 | |
| SCHEMBL11302784 | 0.79 | HTR2B (0.55) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL14945596 | 0.79 | HDAC4 (0.42) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL22994705 | 0.78 | ALDH1A1 (0.44) | HTR2CHTR2AHTR2BADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217184-B2 | Process for producing optically active cis-silyl olefin oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217184-B2 | Process for producing optically active cis-silyl olefin oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100305338-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CIS-SILYL OLEFIN OXIDE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100305338-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CIS-SILYL OLEFIN OXIDE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-02 | — | — | US | disclosed |
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305338-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CIS-SILYL OLEFIN OXIDE COMPOUND | CYP51A1, MSMO1, SQLE | HTR2C 4212/4885HTR2A 4580/4885HTR2B 3747/4885 |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | HTR2C 2272/4885HTR2A 3568/4885HTR2B 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.